This tragic case is yet another example of why the FDA must immediately reinstate stronger safety protections and oversight surrounding the abortion drug regimen, including mifepristone.
For years, safety safeguards once required women to: • receive in-person medical evaluations, • confirm gestational age and rule out ectopic pregnancy, • obtain physician oversight, • and receive follow-up care after taking these powerful drugs.
The previous Administration in D.C. removed those standard of care protections … and surround states aggressivly market death through expanded tele-health distribution, mail-order access, and online trafficking networks.
The result is increasing danger, abuse, coercion, and criminal misuse. For months we have been appealing and pleading and waiting the current Congress, the current Adminstration and the FDA to take ACTION.
Abortion-inducing drugs are not harmless. They are powerful pharmaceuticals specifically designed to end the life of an unborn child while placing women at risk for hemorrhage, infection, incomplete abortion, emotional trauma, and medical complications — often without direct physician supervision.
Women deserve real healthcare and real protections — not dangerous mail-order abortion schemes with little accountability. |